ES510649A0 - "procedimiento para la preparacion de 9-(2-(3-indolil)-etil)-1-oxa-4,9-diazaspiro (5.5) undecan-3-onas". - Google Patents

"procedimiento para la preparacion de 9-(2-(3-indolil)-etil)-1-oxa-4,9-diazaspiro (5.5) undecan-3-onas".

Info

Publication number
ES510649A0
ES510649A0 ES510649A ES510649A ES510649A0 ES 510649 A0 ES510649 A0 ES 510649A0 ES 510649 A ES510649 A ES 510649A ES 510649 A ES510649 A ES 510649A ES 510649 A0 ES510649 A0 ES 510649A0
Authority
ES
Spain
Prior art keywords
indolil
etil
onas
undecan
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES510649A
Other languages
English (en)
Spanish (es)
Other versions
ES8306373A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of ES8306373A1 publication Critical patent/ES8306373A1/es
Publication of ES510649A0 publication Critical patent/ES510649A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES510649A 1981-03-23 1982-03-22 "procedimiento para la preparacion de 9-(2-(3-indolil)-etil)-1-oxa-4,9-diazaspiro (5.5) undecan-3-onas". Granted ES510649A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/246,459 US4332804A (en) 1981-03-23 1981-03-23 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones

Publications (2)

Publication Number Publication Date
ES8306373A1 ES8306373A1 (es) 1983-06-01
ES510649A0 true ES510649A0 (es) 1983-06-01

Family

ID=22930776

Family Applications (1)

Application Number Title Priority Date Filing Date
ES510649A Granted ES510649A0 (es) 1981-03-23 1982-03-22 "procedimiento para la preparacion de 9-(2-(3-indolil)-etil)-1-oxa-4,9-diazaspiro (5.5) undecan-3-onas".

Country Status (19)

Country Link
US (1) US4332804A (enExample)
EP (1) EP0061333B1 (enExample)
JP (1) JPS57169485A (enExample)
KR (1) KR830009094A (enExample)
AT (1) ATE17249T1 (enExample)
AU (1) AU557094B2 (enExample)
BR (1) BR8201589A (enExample)
DE (1) DE3268225D1 (enExample)
DK (1) DK129282A (enExample)
ES (1) ES510649A0 (enExample)
FI (1) FI820998A7 (enExample)
IE (1) IE52652B1 (enExample)
IL (1) IL65310A (enExample)
NO (1) NO820937L (enExample)
NZ (1) NZ200085A (enExample)
PH (1) PH17233A (enExample)
PL (1) PL235561A1 (enExample)
PT (1) PT74626B (enExample)
ZA (1) ZA821929B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977178A (en) * 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4879391A (en) * 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4861880A (en) * 1982-09-20 1989-08-29 Pfizer Inc. 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
NZ533567A (en) * 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
JP2005533813A (ja) * 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
NO2200610T3 (enExample) * 2007-09-21 2018-06-09
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
TN2018000122A1 (en) 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
FI3697795T3 (fi) 2017-10-17 2024-02-23 Acondicionamiento Tarrasense (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) * 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US3574204A (en) * 1969-07-03 1971-04-06 Yoshitomi Pharmaceutical Piperidine spiro compounds
CA952908A (en) * 1970-02-27 1974-08-13 Yoshitomi Pharmaceutical Industries Benzodioxane derivatives
US3723442A (en) * 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof

Also Published As

Publication number Publication date
ZA821929B (en) 1983-11-30
JPS57169485A (en) 1982-10-19
ES8306373A1 (es) 1983-06-01
AU557094B2 (en) 1986-12-04
PT74626A (en) 1982-04-01
PH17233A (en) 1984-07-03
FI820998L (fi) 1982-09-24
NZ200085A (en) 1985-07-12
IL65310A (en) 1985-03-31
PL235561A1 (enExample) 1982-10-25
EP0061333A1 (en) 1982-09-29
BR8201589A (pt) 1983-02-08
EP0061333B1 (en) 1986-01-02
IE820648L (en) 1982-09-23
NO820937L (no) 1982-09-24
AU8176982A (en) 1982-09-30
FI820998A7 (fi) 1982-09-24
DE3268225D1 (de) 1986-02-13
ATE17249T1 (de) 1986-01-15
PT74626B (en) 1983-12-19
IE52652B1 (en) 1988-01-06
DK129282A (da) 1982-09-24
US4332804A (en) 1982-06-01
KR830009094A (ko) 1983-12-17
IL65310A0 (en) 1982-05-31

Similar Documents

Publication Publication Date Title
AU557094B2 (en) 9-(2-(3-indolyl)ethyl)-1-oxa-4,9-diazaspiro(5,5)undecan 3-ones
AU580321B2 (en) New tryptamine derivatives, a process for their preparation, and their use
ES509242A0 (es) "procedimiento para preparar nuevos compuestos de cefem".
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
IE820401L (en) N-£4-(indolyl)-piperidino-alkyl|-benzimidazolines
ZA858699B (en) Quinolonecarboxylic acid derivatives
AU2636988A (en) New 2-(piperazinyl)-2-substituted flavonoid derivatives, processes for preparing them and pharmaceutical compositions containing them
AU562182B2 (en) Bicyclo(4,2,0)1,3,5-octatriene derivatives
NO170580C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater
ES8504180A1 (es) Procedimiento para preparar nuevos derivados de piperidina
GR3006108T3 (enExample)
BE896098A (fr) Procede de modulation de la reponse immunitaire avec des dibenzocycloheptenylidenes